Teriparatide (Forteo) for Osteoporosis

American Family Physician

Volumn 69, Issue 8, 2004, Pages 1983-1984

  Bazaldua, Oralia V ^a   Bruder, Jan ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; DRUG TOLERABILITY; HIP FRACTURE; HUMAN; HYPOTENSION; LEG CRAMP; NAUSEA; NONHUMAN; OSTEOPOROSIS; OSTEOSARCOMA; RISK ASSESSMENT; SHORT SURVEY; TREATMENT WITHDRAWAL;

BONE DENSITY; HUMANS; OSTEOPOROSIS; TERIPARATIDE;

EID: 1942437385     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (3)

1. Forteo package insert. 2002. Forteo (teriparatide) by Eli Lilly and Company. Accessed online March 10, 2004, at: http://pi.lilly.com/us/forteo-pi.pdf.
2. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
3. 2003 Drug topics. Red Book. Montvale, NJ: Medical Economics Data, 2003.